SOLIGENIX, INC.

Listed Company

SNGXCIK 0000812796NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

—

Total Assets

$9.24M

Equity

$5.29M

Shares Out

14.82M

Op. Cash Flow

$-10.27M

SNGX$0.36−74.07% · past yearDBEQ Basic

Daily closing prices

Business

Soligenix is a late-stage biopharmaceutical company developing products for rare diseases with unmet medical needs. It operates two segments: Specialized BioTherapeutics, advancing HyBryte™ (synthetic hypericin photodynamic therapy) for cutaneous T-cell lymphoma through Phase 3 trials, plus programs in psoriasis and dusquetide-based therapies for Behçet's Disease and oral mucositis; and Public Health Solutions, developing government-funded vaccine candidates including RiVax® (ricin toxin), filovirus vaccines, and a COVID-19 candidate using its proprietary ThermoVax® heat-stabilization platform. The company outsources manufacturing and seeks distribution partnerships for commercialization.

Summary from 10-K filed 2026-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	—	119,371	839,359	948,911	824,268
Cost of revenues	—	−119,371	−742,048	−550,822	−728,640
Research and development	7	5	3	8	8
General and administrative	4	4	4	7	5
Total operating expenses	12	9	8	15	13
Loss from operations	−12	−9	−8	−14	−13
Foreign currency transaction (loss) gain	−11,814	1,591	1,483	−30,549	−39,361
Interest income, net	270,170	213,975	−49,129	−822,611	−904,502
Research and development incentives	—	−25,488	23,784	132,869	174,770
CARES Act employee retention credit	—	312,753	120,771	—	—
Other income	125	43	43,223	—	—
Change in fair value of convertible debt	—	260,933	43,066	—	—
Total other income	258,481	763,807	−210,593	−714,370	−316,755
Net loss before income taxes	−12	−9	−8	−15	−13
Income tax benefit	506,615	409,114	2	1	864,742
Net loss applicable to common stockholders	−11	−8	−6	−14	−13
Basic net loss per share (in Dollars per share)	−2.14	−4.98	−12.66	−4.81	−4.69
Diluted net loss per share (in Dollars per share)	−2.14	−4.98	−12.66	−4.81	−4.69
Basic weighted average common shares outstanding (in Shares)	5	2	484,995	3	3
Diluted weighted average common shares outstanding (in Shares)	5	2	484,995	3	3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	8	8	8	13	26
Deferred issuance cost	18,543	103,847	—	—	—
Prepaid expenses and other current assets	894,311	905,269	866,014	274,209	282,903
Total current assets	9	9	10	14	27
Security deposit	22,777	22,777	22,777	22,777	22,777
Furniture and equipment, net	8,772	6,113	11,927	18,481	22,220
Right-of-use lease assets	354,965	108,963	229,834	340,987	106,155
Total assets	9	9	10	14	27
Accounts payable	1	667,896	1	4	3
Accrued expenses	2	2	2	2	3
Accrued compensation	488,125	336,442	251,115	336,692	302,936
Lease liabilities, current	114,023	111,862	121,765	108,948	106,151
Convertible debt	—	1	2	10	—
Total current liabilities	4	5	6	17	6
Lease liabilities, net of current portion	244,121	—	111,862	233,627	—
Total liabilities	4	5	7	17	16
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, 350,000 shares authorized; none issued or outstanding at December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.001 par value; 75,000,000 shares authorized; 10,086,130 and 2,514,499 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	10,086	2,514	649	2,909	2,859
Additional paid-in capital	250	238	228	217	216
Accumulated other comprehensive income	45,789	45,789	22,243	24,747	41,942
Accumulated deficit	−245	−234	−226	−220	−206
Total shareholders' equity	5	4	3	−2	11
Total liabilities and shareholders' equity	9	9	10	14	27

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−11	−8	−6	−14	−13
Amortization and depreciation	3,224	5,814	6,554	24,562	34,161
Non-cash lease expense	114,602	120,871	111,153	112,714	116,290
Share-based compensation	587,583	329,815	370,182	333,389	361,559
Issuance of common stock to vendors for services	76,600	15,800	73,000	212,003	27,500
Contracts and grants receivable	—	171,254	−56,124	23,759	64,885
Prepaid expenses and other current assets	10,958	−39,255	−591,805	8,694	−57,430
Research and development incentives receivable	—	48,643	90,016	73,374	205,237
Operating lease liability	−114,322	−121,765	−108,948	−111,122	−116,290
Accounts payable and accrued expenses	−16,501	−492,613	−3	396,651	1
Accrued compensation	151,683	85,327	−85,577	33,756	−572,160
Net cash flows from operating activities	−10	−8	−9	−13	−12
Purchases of furniture and equipment	−5,883	—	—	—	—
Net cash flows from investing activities	−5,883	—	—	−13,073	−11,789
Proceeds from issuance of common stock pursuant to At Market Issuance Sales Agreement	5	1	3	79,354	20
Proceeds from issuance of common stock and pre-funded warrants	7	5	8	—	—
Proceeds from the exercise of warrants	305,241	4	—	—	—
Issuance costs associated with warrant inducement	—	−374,774	—	—	—
Convertible debt repayments	−1	−1	−7	—	—
Net cash flows from financing activities	10	8	4	76,821	19
Effect of exchange rate on cash and cash equivalents	—	14,885	27,146	−99,009	60,642
Net increase (decrease) in cash and cash equivalents	116,639	−626,644	−5	−13	7
Cash paid for state income taxes	122,155	42,162	20,730	16,043	7,727
Cash paid for interest	35,044	227,735	552,058	857,411	668,715
Operating lease	139,500	136,917	133,817	133,300	133,300
Pontifax conversion of portion of debt principal into common stock	—	254,256	—	—	—
Right-of-use assets obtained in exchange for lease liabilities	360,604	—	—	347,546	—
Deferred issuance cost reclassified to additional paid-in capital	103,847	250,698	20,208	60	33,257
Offering costs included in accounts payable and accrued expenses	67,850	—	—	—	—
Warrant modification - incremental value	—	7	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is SOLIGENIX, INC.'s CIK number?

SOLIGENIX, INC.'s SEC CIK number is 0000812796 (812796). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find SOLIGENIX, INC.'s SEC filings?

All of SOLIGENIX, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →